Novel Seminal Plasma Test Accurately Predicts Sperm Retrieval in NOA Patients

New research presented at the 42nd Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) in London, UK, from July 5 to 8, 2026, introduces a promising non-invasive seminal plasma assay designed to accurately predict sperm retrieval outcomes in men suffering from non-obstructive azoospermia (NOA). This significant development, reported by the European Medical Journal (EMJ) on July 7, 2026, could transform the diagnostic approach for male infertility, offering a less invasive and more effective method to guide treatment decisions. Non-obstructive azoospermia is a severe form of male infertility characterized by severely impaired sperm production, meaning that surgical sperm retrieval, often through microdissection testicular sperm extraction (micro-TESE), frequently represents the only opportunity for these men to father biological children. However, micro-TESE is an invasive procedure with a success rate of only around 60%, leading many patients to undergo surgery without benefit. The need for reliable, non-invasive predictive tools has been a long-standing challenge in reproductive medicine. The groundbreaking study, which was presented at ESHRE 2026, utilized a multi-omics analysis of seminal plasma, combining RNA sequencing, DNA sequencing, and proteomic profiling. Researchers evaluated this approach in 42 men with idiopathic NOA, meticulously excluding patients with known genetic conditions like Klinefelter syndrome or Y chromosome microdeletions, and those with a history of chemotherapy or radiotherapy. The analysis successfully identified two key biomarkers, TPTE2 and NEU1, which consistently distinguished patients with successful sperm retrieval from those without. According to the findings, all nineteen men in the study who showed overexpression of both TPTE2 and NEU1 biomarkers had spermatozoa successfully retrieved following micro-TESE. Conversely, none of the twenty-three men with underexpression of these genes had successful sperm retrieval. This stark contrast highlights the potential of these biomarkers as highly accurate predictors. Notably, conventional predictors such as testicular volume and serum follicle-stimulating hormone (FSH) levels, which are currently used in clinical practice, did not show significant differences between the two groups, underscoring the superiority of the new seminal plasma assay. Beyond just successful retrieval, the study also reported encouraging outcomes for those who benefited from the procedure. Among men from whom spermatozoa were successfully retrieved, fertilization was achieved in approximately 51% of injected oocytes, leading to a clinical pregnancy rate of 45% and eight live births. These results demonstrate the clinical utility of the retrieved sperm for assisted reproductive technologies like intracytoplasmic sperm injection (ICSI). The researchers also indicated preliminary evidence suggesting that a rapid RNA fluorescence in situ hybridization (FISH) assay could deliver comparable findings within days, rather than weeks, which would be a significant advantage for patient management and counselling. The European Medical Journal (EMJ), which reported on these findings, is an independent, open-access eJournal recognized for delivering insights into medical advancements across various therapeutic areas, including reproductive health. EMJ's content undergoes peer review and adheres to high-quality controls, ensuring its credibility within the medical community. The European Society of Human Reproduction and Embryology (ESHRE) is a globally recognized authority in reproductive science and medicine, and its annual meetings are premier events for presenting cutting-edge research. The presentation of this data at ESHRE 2026 signifies its importance and relevance to the global reproductive medicine community. While the findings are highly promising, the authors emphasize that further validation is needed before the seminal plasma assay can be adopted into widespread clinical practice. This is a standard and responsible scientific caveat, acknowledging the need for larger studies, possibly multi-center trials, to confirm the reliability and generalizability of these results across diverse patient populations. However, the study represents a crucial step forward in improving patient selection for surgical sperm retrieval, potentially saving many men with NOA from undergoing unnecessary and invasive procedures, reducing physical and psychological burden, and optimizing fertility treatment pathways. For an Indian audience, where infertility rates are significant and access to advanced, less invasive diagnostics can be crucial, this research holds substantial future relevance. This area of research, focused on seminal plasma biomarkers, is an active field, with similar promising studies being presented at previous ESHRE meetings, such as an abstract for ESHRE 2025 on a multi-omics panel to predict sperm retrieval success.

Frequently Asked Questions

Read Full Story on Quick Digest